Department for Drug Design, University of Groningen, A. Deusinglaan 1, 9700 AD Groningen (The Netherlands) http://www.drugdesign.nl/.
Angew Chem Int Ed Engl. 2014 Feb 24;53(9):2286-8. doi: 10.1002/anie.201307906. Epub 2014 Jan 28.
No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related. Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies. Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease.
没有其他癌症治疗靶点类像程序性死亡受体 1（PD-1）途径那样令人兴奋。抗 PD-1 和 PD-1 配体的抗体代表了治疗上的突破，是广泛有效和持久的癌症免疫疗法的首例。癌症首次似乎从一种通常无法治愈的疾病转变为一种“临床可管理”的疾病。
